Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

W. J. Gradishar, S. B. Wedam, M. Jahanzeb, J. Erban, S. A. Limentani, K. T. Tsai, S. R. Olsen, S. M. Swain

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Background: To evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. Patients and methods: Forty-five patients were planned to receive four cycles of docetaxel 100mg/m2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated. Results: After four cycles of neoadjuvant docetaxel, the clinical response rate within the breast was 59% (95% CI 42% to 73%) and overall (breast and axilla) was 49% (95% CI 38% to 72%) in the intention-to-treat (ITT) population. At the time of surgery, 10% (n=4) of patients had a pathologic complete response (pCR) in the breast, 27% (n=11) had a pCR within the axillary lymph nodes, and 7% (n=3) had a pCR in the breast and axilla (95% CI 2% to 21%). An additional 5% (n=2) had minimal residual invasive tumor (<5mm). The 5-year overall survival rate was 80%. The percentage of patients with grade 3/4 neutropenia was similar during docetaxel (93%) and AC (86%), while a greater percentage of patients had febrile neutropenia during docetaxel treatment (27%) compared with AC treatment (7%). Conclusions: Neoadjuvant docetaxel followed by surgery, adjuvant AC, hormonal therapy where indicated, and RT is an active regimen for patients with stage III breast cancer.

Original languageEnglish (US)
Pages (from-to)1297-1304
Number of pages8
JournalAnnals of Oncology
Volume16
Issue number8
DOIs
StatePublished - Aug 2005
Externally publishedYes

Keywords

  • Neoadjuvant docetaxel
  • Stage II breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer'. Together they form a unique fingerprint.

Cite this